Your Messages Inbox
Your Article Summary
See Latest ArticlesFarletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
Morphotek, 09/25/09
Morphotek, Inc., a subsidiary of Eisai Corporation of North America, announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum–sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab is a humanized monoclonal antibody that targets the Folate Receptor Alpha.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
Lundbeck, 11/30/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Article Search
Sponsor